Depleted Gut Bacteria May Drive Memory Decline in Older Adults With High Blood Pressure

Roughly 55 to 60 percent of Chinese adults aged 60 and older have hypertension, and an estimated 15 to 20 percent of that same age group show signs of amnestic mild cognitive impairment (aMCI), a memory disorder that frequently progresses to Alzheimer's disease. A new study published in Frontiers in Immunology by Zongxin Ling and colleagues examined what happens when these two conditions collide inside the gut, and the results suggest the microbial damage is more severe than either condition produces on its own.

Depleted SCFA Bacteria and Opportunistic Pathogens in Hypertensive aMCI

The researchers enrolled 205 older adults from Lishui, China, between May and August 2024, dividing them into three groups: 52 healthy controls, 83 hypertensive individuals with normal cognition (HTN-CN), and 70 hypertensive subjects with aMCI (HTN-aMCI). Gut microbiota composition was profiled using 16S rRNA gene sequencing of fecal samples, and serum levels of 27 inflammatory mediators were measured by multiplex immunoassay.

The HTN-aMCI group showed a microbial community dominated by Escherichia-Shigella, an enterotype associated with gut barrier disruption, while the control group's microbiota was enriched with Blautia and Collinsella. Three genera critical for producing short-chain fatty acids (SCFAs), the metabolites that dampen inflammation and support gut barrier integrity, were significantly depleted in HTN-aMCI: Roseburia, Blautia, and Faecalibacterium. At the same time, opportunistic pathogens including Enterococcus, Clostridium_sensu_stricto_1, and Streptococcus were enriched. This pattern is consistent with what prior research on gut dysbiosis in hypertension has described as a collapse of microbial cooperation in favor of inflammatory species.

Why This Combination Poses a Heightened Risk for Cognitive Decline

aMCI is not simply age-related forgetfulness. It involves memory decline that exceeds what aging alone explains, without yet meeting criteria for dementia, making it a critical window for intervention. Global estimates put MCI prevalence at around 23.7% in older populations, and hypertension compounds that risk through cerebrovascular damage, chronic inflammation, and oxidative stress.

When dysbiosis reduces SCFA production, gut permeability increases, allowing lipopolysaccharides (LPS), fragments of bacterial cell walls, to enter the bloodstream and activate the immune system. Functional predictions using PICRUSt2 found enhanced LPS biosynthesis pathways in the HTN-aMCI group, alongside reduced capacity for carbohydrate metabolism, which is the metabolic engine that drives SCFA production. The net effect is a microbiome that appears primed to generate inflammatory signals rather than suppress them. This mechanistic chain, from gut dysbiosis to systemic immune activation to neuroinflammation, is increasingly recognized as a route through which gut microbiota changes can accelerate neurodegeneration.

How the Study Isolated the Microbial and Inflammatory Signals

Beyond composition, the team analyzed co-occurrence networks, maps of how bacterial species interact within the gut ecosystem. In healthy controls, 78.2 percent of bacterial correlations were positive, meaning species tended to support each other. In the HTN-aMCI group, that figure dropped to 55.1 percent, while the network itself became sparser, with only 158 edges and a density of 0.124, compared to denser, more cooperative networks in the other groups. Reduced clustering and lower average degree scores signal an ecologically destabilized microbiome.

On the inflammatory side, HTN-aMCI patients showed a prominent Th17 immune signature, with elevated IL-17, IL-6, and IL-1b, alongside increases in Th1-related markers like TNF-a and IL-2. Critically, Blautia abundance correlated negatively with these inflammatory markers and positively with MoCA cognitive scores after false discovery rate correction. Pathobionts like Intestinibacter and Subdoligranulum showed the opposite pattern, correlating positively with IL-17 and RANTES. A random forest classifier using eight bacterial genera discriminated HTN-aMCI from HTN-CN with an area under the curve of 0.66, modest but suggestive of diagnostic potential.

Key Limitations of a Cross-Sectional Snapshot

The study's design prevents causal conclusions. Because all samples were collected at a single point in time, it is impossible to determine whether the microbial imbalance preceded cognitive decline, developed alongside it, or is partly a consequence of it. Longitudinal cohorts tracking microbiota over years would be needed to establish directionality.

Functional pathway predictions relied on PICRUSt2, a computational inference tool rather than direct shotgun metagenomics or metabolomics, meaning the metabolic claims are probabilistic rather than measured. The study population was exclusively elderly Chinese adults from one city, which limits how far the findings can be extended to other ethnic groups or geographies. Residual confounding from diet, physical activity, and sleep, factors the study could not fully control, also cannot be ruled out. Researchers noted that antihypertensive medication use did not differ significantly between HTN-CN and HTN-aMCI groups, suggesting drugs alone do not explain the microbial divergence, but the influence of specific drug classes on microbiota composition warrants closer examination.

Probiotic and Dietary Strategies as Potential Next Steps

The authors propose several therapeutic avenues worth testing in future trials. Replenishing depleted genera like Blautia and Faecalibacterium through probiotic supplementation, increasing fermentable dietary fiber to boost SCFA production, and fecal microbiota transplantation (FMT) from healthy donors are all strategies with a growing evidence base. Reviews of gut-targeted therapies for cognitive impairment suggest that probiotics and high-fiber diets reduce systemic inflammation in ways that could plausibly slow aMCI progression, though randomized controlled trials in hypertensive populations specifically remain scarce.

The practical takeaway from this study is that the gut microbiome of an older adult with both hypertension and early memory loss looks distinct enough from that of a hypertensive peer with intact cognition to warrant its own clinical attention. Whether correcting that imbalance can slow the slide toward Alzheimer's disease is the question that only longer, interventional studies can answer.

Evidence rating

EMERGING — 80/100

Caveats:

• Cross-sectional design: this study shows associations, not cause and effect — it cannot determine whether gut dysbiosis drives cognitive decline or vice versa.
• Microbial functional predictions are modeled (PICRUSt2), not directly measured by metabolomics or shotgun sequencing.
• Participants are exclusively elderly Chinese adults from a single region; findings may not generalize to other populations.
• The diagnostic panel of 8 microbial genera reached only a modest AUC of 0.66, limiting clinical utility.
• Funding source was not disclosed by the authors.

Cross-sectional study of 205 older Chinese adults using 16S rRNA sequencing and multiplex cytokine immunoassay. Findings are associative — the design cannot establish whether gut dysbiosis precedes or results from cognitive impairment. Functional pathway data are predicted rather than directly measured. The study has not yet been independently replicated in an external cohort.

References

1. Zongxin Ling, Yiwen Cheng, Xiaocui Xu, et al. (2026). Gut dysbiosis and systemic inflammation in elderly hypertensive patients with amnestic mild cognitive impairment. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1871446
2. Lei Qu, Zhouyan Dong, Songcui Ma, et al. (2022). Gut Microbiome Signatures Are Predictive of Cognitive Impairment in Hypertension Patients—A Cohort Study. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2022.841614
3. Nader Salari, Fateme Lotfi, Amir Abdolmaleki, et al. (2025). The global prevalence of mild cognitive impairment in geriatric population with emphasis on influential factors: a systematic review and meta-analysis. BMC Geriatrics. https://doi.org/10.1186/s12877-025-05967-w
4. Jiaheng Yang, Xiangzhun Song, Su Yan, Qianxun Li, Wenying Yang (2026). The gut microbiota influences neurodegenerative diseases through the gut-brain axis: molecular mechanisms and effects on immune function. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1739329
5. Yi Sun, Liliana C Baptista, Lisa M Roberts, et al. (2019). The Gut Microbiome as a Therapeutic Target for Cognitive Impairment. The Journals of Gerontology: Series A. https://doi.org/10.1093/gerona/glz281